药物对比
Alogliptin vs Tolazamide
比较Alogliptin（DPP-4抑制剂）与Tolazamide（磺脲类）治疗2型糖尿病：疗效、低血糖风险、心力衰竭警告及患者适用性。
此页面暂无可用的对比维度。
临床背景
This comparison is typically triggered when evaluating a switch from an older first-generation sulfonylurea to a DPP-4 inhibitor in type 2 diabetes patients with cardiovascular or hypoglycemia concerns.
结论
Alogliptin and Tolazamide both lower blood glucose in type 2 diabetes but differ markedly in mechanism, hypoglycemia risk, and cardiovascular safety, so the better choice is highly patient-specific.
全部药物对比